The Unforeseen Ripple: How Trump's Drug Pricing Push Could Have Raised Global Costs

When Geopolitics Hits Home: The Unsettling Shadow of an Iran Conflict on Our Medicine Cabinet

The Persistent Echo: Trump's Most Favored Nation Policy Still Shapes Drug Pricing Debates

Hims & Hers Steps into the Doctor's Office: Convenience vs. Comprehensive Care

A Glimmer of Hope for Kidney Disease: Vertex's Breakthrough in IgA Nephropathy

The FDA's Quiet Retreat: Fewer Public Debates Amid Rising Controversy

The Price of Life: Will South Africa Gain Access to Gilead's Breakthrough HIV Drug?

Virginia's Bold Move: A New Era for Prescription Drug Affordability

The Shifting Sands of Pharma: FDA's Grip, Global Ambitions, and the Future of Medicine

A Major Setback: FDA Halts uniQure's Huntington's Gene Therapy Trial

The End of an Era: Doug Ingram Prepares to Retire from Sarepta, Elizabeth Barrett Named Successor

The Grand Ambition of Early Cancer Detection: Unpacking Tests Like Galleri

A Looming Showdown: Can RFK Jr. and Dr. Maha Force the FDA to Confront the Ultra-Processed Food Crisis?

The Shifting Tides of American Health: What's Next for HHS Post-2026?

A Game-Changer on the Horizon: Disc Medicine's Bitopertin and the FDA's Looming Decision

Unpacking Trump's Vision for 340B: A Pilot Program's Complex Ripples

Pharmalot's Pulse Check: Navigating Pharma's Twists and Turns

The Shifting Sands of Pharma: Innovation, Access, and Lingering Questions in Early 2026

The J.P. Morgan Healthcare Conference 2026: Day 2 Unpacked

Unlocking New Frontiers: How Revolution Medicines and Merck Are Redefining the Cancer Fight

Alnylam's Ambitious Five-Year Vision: Betting Big on Amvuttra and Beyond

The Evolving Landscape of Pharma and Biotech Employment

Unpacking the Ambition: Trump's Most-Favored-Nation Drug Pricing Push

Cytokinetics' Myqorzo Secures Landmark FDA Approval, Reshaping HCM Treatment Landscape

Navigating the Complex Currents of Modern Pharmaceuticals

The 'Skinny Label' Showdown: How a Supreme Court Case Could Redefine Generics and Drug Prices

Incyte Unveils Game-Changing Myelofibrosis Data at ASH 2025

A Glimmer of Hope: Syndax's Novel AML Drug Shines Bright at ASH Meeting

A New Dawn in Cancer Detection: Freenome's Bold Move Towards Public Markets

Unpacking Pharma's Future: Costs, Generics, and the Tug-of-War for Access

Unlocking Affordable Medicine: A Call for Smarter Biosimilar Regulation

A Noteworthy Platform: Vaccine Critic Aaron Siri Addresses the ACIP

The Pharmaceutical Pulse: A Year-End Reflection on Innovation, Politics, and Public Trust in 2025

The Anticipation Builds: ASH 2025 and the Evolving Landscape of Blood Cancer Therapies

The Looming Shadow Over American Science: A Critical Look at Funding Threats

The FDA's Bold New Vision: Could One Clinical Trial Be Enough for Drug Approval?

A Glimmer of Hope for Hair Loss Sufferers: Cosmo Pharma's Breezula Delivers in Landmark Trial

A Notable Shift: Dr. Theresa Michele Steps Down from FDA's Nonprescription Drug Leadership

A Beacon of Hope: Capricor's Cell Therapy Shows Remarkable Heart Improvements in Duchenne Patients